🇺🇸 FDA
Pipeline program

IMD-1041

IMD-10412003-1

Phase 2 small_molecule active

Quick answer

IMD-1041 for Chronic Obstructive Pulmonary Disease is a Phase 2 program (small_molecule) at Design Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Design Therapeutics
Indication
Chronic Obstructive Pulmonary Disease
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials